MPD doctors discuss benefits of 2 JAK2 Inhibitors
Drs. Ayalew Tefferi and Animesh Pardanani presented data at ASH on the benefits of two drugs currently in clinical trials: TG101348 and CYT387. TG101348 is currently being tested in myelofibrosis patients and has been shown to reduce constitutional symptoms as well as reduction in spleen size and JAK burden in many of the patients. CYT387 is also being tested in myelofibrosis patients and also reduces spleen size as well as helps with symptoms, but also works to reduce the affects of anemia in myelofibrosis patients.